Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 17/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.51 |
| ▸ | THRB | P10828 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5496438 | 0.89 | TGFBR1 (0.56) | TGFBR1MAPK14THRB | |
| SCHEMBL2042895 | 0.89 | TGFBR1 (0.49) | TGFBR1MAPK14THRBNSD3 | |
| SCHEMBL376179 | 0.87 | TGFBR1 (0.67) | TGFBR1MAPK14THRBALDH1A1 | |
| SCHEMBL2049330 | 0.86 | TGFBR1 (0.59) | TGFBR1MAPK14THRB | |
| Fluoromethane SCHEMBL27755992 | 0.85 | TGFBR1 (0.64) | TGFBR1MAPK14THRBALDH1A1 | |
| SCHEMBL2044086 | 0.82 | TGFBR1 (0.49) | TGFBR1MAPK14THRB | |
| SCHEMBL6683670 | 0.81 | TGFBR1 (0.48) | TGFBR1MAPK14THRB | |
| SCHEMBL2045360 | 0.79 | TGFBR1 (0.47) | TGFBR1MAPK14THRB | |
| SCHEMBL5487055 | 0.78 | IDO1 (0.40) | TGFBR1MAPK14HTR1AADRA1DADRA1A | |
| SCHEMBL2049534 | 0.78 | TGFBR1 (0.60) | TGFBR1MAPK14THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115870-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON RESEARCH, LTD. (US) | 2012-05-10 | — | — | US | claimed |
| US-20110160210-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2011-06-30 | — | — | US | claimed |
| CN-101330914-A | Control of intraocular pressure using ALK5 modulation agents | ALCON INC (CH) | 2008-12-24 | — | — | CN | claimed |
| EP-1959949-A2 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | Alcon, Inc. (CH) | 2008-08-27 | — | — | EP | claimed |
| US-20070142376-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2007-06-21 | — | — | US | claimed |
| WO-2007070866-A2 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2007-06-21 | — | — | WO | claimed |
| WO-2004026302-A1 | METHODS OF INHIBITING TGF BETA WITH SUBSTITUTED PYRAZOLES | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | claimed |
| US-20120115870-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON RESEARCH, LTD. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20110160210-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2011-06-30 | — | — | US | disclosed |
| CN-101330914-A | Control of intraocular pressure using ALK5 modulation agents | ALCON INC (CH) | 2008-12-24 | — | — | CN | disclosed |
| EP-1959949-A2 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | Alcon, Inc. (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070142376-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2007-06-21 | — | — | US | disclosed |
| WO-2007070866-A2 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2007-06-21 | — | — | WO | disclosed |
| WO-2004026302-A1 | METHODS OF INHIBITING TGF BETA WITH SUBSTITUTED PYRAZOLES | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115870-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALK, ACVR1, ACVR2A | TGFBR1 14/4885MAPK14 890/4885THRB 314/4885 |
| US-20110160210-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALK, ACVR1, ACVR2A | TGFBR1 14/4885MAPK14 890/4885THRB 314/4885 |
| US-20070142376-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALK, ACVR1, ACVR2A | TGFBR1 14/4885MAPK14 890/4885THRB 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.